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Introduction: Leishmaniasis remains one of the neglected tropical diseases. 
Repurposing existing drugs has proved to be successful for treating neglected 
tropical diseases and combination therapy is a strategic alternative for treatment of 
infectious diseases. Auranofin, aluvia and sorafenib are FDA approved drugs used in 
treatment of diverse diseases by acting on different essential biological enzymes.  
Objective: In the current work mono- and combined therapeutic effects of the three 
drugs have been evaluated against Leishmania infantum. 
Material and methods: The leishmanicidal effects of the three drugs on 
promastigotes were compared in vitro as regards the parasite count, the 
concentration of a drug that gives half-maximal response and the ultrastructural 
changes of the parasite. Determination of fraction inhibitory concentration index of 
combined drugs in a two way manner and the activity of the three drugs together 
was calculated to determine the synergetic effect. 
Results: The three drugs as monotherapy were effective but auranofin had the best 
anti-leishmanial effect , its EC50 was 1.5 µM, whereas sorafinib reduced parasite 
growth at EC50 =2.5 µM. Scanning electron microscopy of promastigotes from all 
treated media showed distortion in the shape with loss of flagella and bleb formation. 
Acidocalcinosis was evident by transmission electron microscopy with all treatments, 
suggesting apoptosis. Treatment with aluvia showed signs of autophagy. The two-
way combination of the drugs led to additive interactions while combination of the 
three drugs showed synergistic action. 
Conclusion: Each drug when used as monotherapy against Leishmania is effective, 
whereas combination therapy is more effective and superior than individual drugs 
due to additive or synergistic effects. 
Key words: Leishmania infantum; drug synergism; apoptosis; autophagy. 
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Introducción. La leishmaniasis sigue siendo una de las enfermedades tropicales 
desatendidas. La reutilización de medicamentos existentes ha demostrado ser 
exitosa para tratar enfermedades tropicales desatendidas y la terapia combinada es 
una alternativa estratégica para el tratamiento de enfermedades infecciosas. 
Auranofin, aluvia y sorafenib son medicamentos aprobados por la FDA utilizados en 
el tratamiento de diversas enfermedades al actuar sobre diferentes enzimas 
biológicas esenciales. 
Objetivo. En el trabajo actual, se han evaluado los efectos terapéuticos mono y 
combinados de los tres fármacos contra Leishmania infantum. 
Material y métodos. Los efectos leishmanicidas de los tres fármacos sobre los 
promastigotos se compararon in vitro en cuanto al recuento de parásitos, la 
concentración de un fármaco que proporciona una respuesta semimáxima y los 
cambios ultraestructurales del parásito. La determinación del índice de concentración 
inhibitoria de fracciones de fármacos combinados de dos maneras y la actividad de 
los tres fármacos juntos se calculó para determinar el efecto sinérgico. 
Resultados. Los tres medicamentos como monoterapia fueron efectivos, pero la 
auranofina tuvo el mejor efecto antileishmanial, su CE50 fue de 1,5 µM, mientras que 
el sorafinib redujo el crecimiento del parásito a la CE50 = 2,5 µM. La microscopía 
electrónica de barrido de promastigotes de todos los medios tratados mostró 
distorsión en la forma con pérdida de flagelos y formación de ampollas. La 
acidocalcinosis fue evidente por microscopía electrónica de transmisión con todos los 
tratamientos, lo que sugiere apoptosis. El tratamiento con aluvia mostró signos de 
autofagia. La combinación bidireccional de las drogas condujo a interacciones 
aditivas, mientras que la combinación de las tres drogas mostró una acción sinérgica. 
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Conclusión. Cada medicamento cuando se usa como monoterapia contra 
Leishmania es efectivo, mientras que la terapia de combinación es más efectiva y 
superior que los medicamentos individuales debido a los efectos aditivos o 
sinérgicos. 
Palabras clave: Leishmania infantum; sinergismo farmacológico; apoptosis; 
autofagia. 
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Leishmaniasis is one of the neglected tropical diseases. It affects as many as 12 
million people living in endemic areas in 98 countries. About 350 million people are 
considered to be at risk, most of them in developing countries (1-3). Leishmania 
species cause a wide clinical spectra that includes cutaneous, mucocutaneous and 
visceral leishmaniasis. The most common is the cutaneous form which causes 
disfiguring and stigmatizing skin lesions whereas mucocutaneous leishmaniasis is 
significantly less common. Visceral leishmaniasis is fatal if not treated (4). 
Currently, limited choices of drugs are used for treatment of leishmaniasis. There are 
no approved vaccines nor prophylactic drugs. Pentavalent antimonial compounds, 
sodium stibogluconate, pentamidine, various amphotericin B (AmB) formulations, 
miltefosine and paromomycin are the approved therapeutics now. Imiquimod and 
sitamaquine are under clinical assessment (5). However, the available drugs have 
limitations which include toxicity, long courses, high costs, undesirable route of 
administration, teratogenicity and drug resistance. Therefore, so far no safe and 
effective anti-leishmania drug is present in the market (6). Recent research funded 
by various organizations is only directed towards clinical trials and diagnostic studies 
of leishmaniasis in endemic countries. Consequently, there is still an urgent need to 
develop new therapeutics for leishmaniasis. 
New drug trials aim at interfering with vital biochemical and metabolic pathways of 
the parasite and in this rationale enzymes are the most important focus. The target 
enzymes in the parasite should have major structural and functional differences from 
the mammalian host ones to achieve selective inhibition of the target sites (7). 
Repurposing existing drugs has been proved to be successful for treating neglected 
tropical diseases. The new uses of Food and Drug Administration (FDA) approved 
drugs are a short cut between the preclinical testing and clinical trials. This strategy 
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reduces the funds needed for the preclinical researches as well as the study of the 
safety profiles and the pharmacological characteristics (8,9). 
In the current study three FDA approved drugs, namely auranofin (Ridura), 
lopinavir/ritonavir (Aluvia) and sorafenib (Nexavar), acting as inhibitors of different 
protease enzymes, have been chosen to study their effect as monotherapy and 
combination therapy on Leishmania infantum (L. infantum). Leishmania proteases 
are very important virulence factors as they are involved in host tissue invasion, 
survival inside macrophages and host immune response modulation. Hence, these 
enzymes are considered good targets in the parasite biology (10). The efficacy of the 
drugs was compared to that of AmB. AmB is a polyene antibiotic which acts on the 
membrane sterols of Leishmania promastigote resulting in a loss of the permeability 
barrier to small metabolites (11). Although, AmB is widely used in treatment of 
leishmaniasis, its toxicity is considerable (12). 
Auranofin (Ridura) is a gold containing drug used in treatment of rheumatoid arthritis. 
It emerged as a strong inhibitor of mammalian thioredoxin reductases (13). Recently 
the drug showed a remarkable antiparasitic activity as a result of inhibition of 
parasitic enzymes involved in the control of the reduction/oxidation (redox) process. 
These enzymes are essential for maintaining intracellular levels of reactive oxygen 
species. Leishmania and other Trypanosomatids contain trypanothione reductase, a 
key enzyme of redox metabolism (14). Trypanothione reductase and mammalian 
glutathione reductase show notable differences in the structure validating specific 
inhibitors designed against trypanothione reductase to be an ideal drug against 
Leishmania parasite without changing the mammalian glutathione reductase activity (7). 
Aluvia is a highly active anti-retroviral therapy (HAART) used against Human 
Immune Deficiency Virus (HIV) (15). The drug is an aspartyl peptidases inhibitor and 
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composed of two anti-retroviral drugs, lopinavir and ritonavir in a ratio of 4:1(16). 
Peptidases enzymes are essential in a wide range of biological functions (17). They are 
recognized as therapeutic targets for important diseases and many micro-organisms 
including Leishmania (18-20). These enzymes are classified into five distinct clans (AA, 
AC, AD, AE and AF) and 16 families according to MEROPS database. Clan AA/ the 
classical aspartic peptidases is further subdivided into eight families of which family A2 
includes the HIV peptidase. In Trypanosomidae, the aspartic peptidases belong to two 
clans; clan AA and clan AD (21). 
In recent decades, co-infection of Leishmania and HIV is increasingly reported in 
endemic areas of leishmaniasis (4). The introduction of HAART has shown a 
recognizable decrease in Leishmania/HIV co-infection as regards incidence, 
pathology and clinical presentation of the disease (22). Experimental studies on 
different Leishmania species using HIV peptidases inhibitors (HIV-PIs) have 
enforced the epidemiological results documenting decrease incidence of 
Leishmania/HIV co-infection after treatment with these drugs (21-25). 
Sorafenib is a multi-kinase inhibitor used for treatment of advanced hepatocellular 
and renal cell carcinoma. Recently, it was identified as active agent against L. 
donovani and different species of Leishmania causing cutaneous leishmaniasis (26). 
Large number of kinases especially cyclin-dependent and mitogen-activated kinases 
are responsible for cell-cycle control in Leishmania. Although kinases are recognized 
as targets for many diseases, they are poorly studied as targets for Leishmania (27). 
The anti-leishmanial potency of sorafenib is due to a non-specific inhibition of many 
diverse protein kinases rather than that of the mammalian kinases (28). 
Combination therapy is a strategic alternative for treatment of infectious diseases. It 
is currently considered as one of the most rational alternatives to increase drug 
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activity, reduce treatment duration and dosage, reduce toxicity and delay or prevent 
drug resistance. It has been efficiently used for treatment of malaria, tuberculosis 
and AIDS (29). However, it is uncommon to treat leishmaniasis by combined drugs 
(30-32). Recently, the need for combination therapy for leishmaniasis has emerged 
(33). 
In the current study the anti-leishmanial effect of auranofin, aluvia and sorafenib 
drugs against L. infantum promastigotes was evaluated compared to the gold 
standard drug for leishmaniasis AmB. The synergistic, additive or antagonistic 
effects of combined therapy were also investigated. The morphological changes of 
the parasite treated with the aforementioned drugs at the ultrastructural level were 
also analyzed.  
Material and methods 
Leishmania strain and its maintenance 
L. infantum MON1 is the visceral leishmaniasis strain used in this study. It was kindly 
provided by Professor Jean Dupouy Camet, president of the European Federation of 
Parasitologists. It was further maintained in the Laboratory of Medical Parasitology 
Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt. L. 
infantum promastigotes were maintained under standard culture conditions in Novey- 
MacNeal-Nicoll (NNN) media. Parasites were sub-cultured every 7 days (34).  
Tested drugs 
Three commercially available FDA-approved drugs were used in this study; 
auranofin, purchased from Abbott; alluvia, purchased from Astellas pharma SPA and 
sorafenib, purchased from Bayer. AmB was used as a gold standard drug.  
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Determination of the in vitro anti-leishmanial activity 
Ten μM stock solutions were prepared from each drug in 1% DMSO. Negative 
control was prepared from 1% DMSO whereas positive control was 10 μM of AmB. 
1×106 Leishmania promastigotes suspended in 100 μL of culture media were 
incubated for three hours before adding the test drugs. After 48 hours of incubation 
with each drug preparation at 25° C, an aliquot of each tube was added to an equal 
amount of a solution containing 0.2% formalin, to stop parasite movement in order to 
facilitate parasite counting using Neubauer chamber (35). Auranofin, aluvia and 
sorafenib were tested in ascending concentrations range from 0.1 to 20 μM. AmB, 
was tested in a dilution range from 0.01 to 17 μM.  
Determination of fraction inhibitory concentration (FIC) index, isobologram 
construction, and classification of the nature of interaction 
Fraction inhibitory concentration (F-IC) is the inhibitory concentration that caused a 
50% decrease in growth (EC50) of promastigotes. It was calculated for each tested 
drug and for each concentration. All tests were performed in triplicate (9). 
To test for synergy, drugs were evaluated in quadruplicate individually to determine 
EC25, each individual compound in a pair was required to inhibit 25±10% of growth 
in untreated media.  
Drug combinations observed to have possible synergism were subjected to formal 
isobologram analysis using the fixed ratio method (36). 
Serial two-fold dilutions were performed in triplicate. For each ratio, an EC50 was 
calculated for each of the drugs. The fractional inhibitory concentrations (FIC) were 
calculated as the following: 
EC50 when in combination / EC50 of drug alone 
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The sum of the FIC was calculated as follows: Σ FICs = FIC drug A + FIC drug B. 
The mean sum of the FIC ( Σ FIC) was calculated as the average of SFIC from the 
three different fixed ratios. The interactions were considered synergistic for  Σ FIC 
≤ 0.5, additive for  Σ FIC between 0.5 and 4, and antagonistic for  Σ FIC >4 (9). 
Ultrastructural study 
Scanning electron microscope (SEM) (JEOL-JSM-25 SII) and transmission electron 
microscope (TEM) (JEOL 100 CX), were used to examine L. infantum promastigotes 
after their treatment with auranofin, aluvia and sorafenib for 48 h at 26° C in 
comparison to positive and negative controls. The specimens were processed for 
SEM and TEM (37,38). 
Statistical analysis 
All parasite burden data were expressed as the mean ± standard deviation. 
Abnormally distributed data was expressed using Median (Min. – Max.) and was 
compared using Kruskal Wallis test. Significance between groups was done using 
Mann Whitney test. A p-value of p < 0.05 was considered statistically significant (39).  
Results 
In vitro anti-leishmanial activity 
It was clear that all used individual drugs, auranofin, aluvia, sorafenib and AmB limit 
in vitro parasite growth after 48 hours of parasite replication. Whereas DMSO had no 
significant effect. Lopinavir/ Ritonavir (aluvia) reduced parasite growth at 1.7 µM. As 
regards to auranofin, the lower drug concentration that was able to limit parasite 
growth by 50% (EC50) was 1.5 µM. Sorafenib and AmB showed the highest EC50 
concentrations (2.5 µM and 2 µM respectively) (table 1 and 2). 
 
 
X
X
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Synergy testing and isobologram analysis 
EC25 values were measured for each of the used drugs in every possible 
combination (table 3). Four combinations were tested in formal isobologram 
analyses in order to quantify the interactions by this standard method. 
Fraction inhibitory concentration (FIC) 
Sum of FICs of combination A (Auranofin+ Lopinavir/Ritonavir) = 1.53+0.45 = 1.98 = 
additive. 
Sum of FICs of combination B (Sorafenib + Lopinavir/ Ritonavir) = 0.59+ 0.8 = 1.39 = 
additive. 
Sum of FICs of combination C (Auranofin + sorafenib) = 1.2+0.48 =1.68 = additive. 
Sum of FICs of combination D (Auranofin+Lopinavir/Ritonavir+sorafenib) = 
0.17+0.12+0.2=0.49 = synergism. 
When these results were statistically studied, aluvia showed no significant difference 
from other drugs either when used alone or in combination form. The growth 
inhibition in auranofin treated media was significantly greater than that treated with 
sorafenib and AmB, but no statistically significant difference was found between it 
and any combination. In spite of reduction in parasite growth, sorafenib was the least 
in potency in comparison to auranofin and combination B, C and D. Combination B, 
C and D showed a significant reduction in the growth of promastigotes compared to 
AmB and combination A (table 4).  
Ultrastructural study 
SEM of the parasites from 48 hours’ culture that were inoculated in fresh media in 
absence of any drug showed normal morphology (figure 1a and b). Promastigotes 
from all treated media showed distortion in the parasite shape with loss of flagella 
and bleb formation. Auranofin treated promastigotes exhibited sever distortion in the 
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parasite shape and some of them showed rounded form (figure 1c). Irregularities in 
the cell membrane of the parasite were highly evident in aluvia treated promastigotes 
(figure 1d), while dimple like structures on cell surface of promastigotes were 
observed well in sorafenib treated parasites (figure 1d). 
Normal ultrastructure contents were detected using TEM for examination of the 
parasites from 48 hours’ culture that were inoculated in fresh media in absence of 
any drug (figure 2a and b). Acidocalcinosis was evident in the parasites from all 
treated media suggesting apoptosis. Auranofin treated promastigotes showed clearly 
evident acidocalcinosis (figure 2c). Aluvia treated promastigotes showed well evident 
acidocalcinosis and degenerated nuclear membrane and chromatin granules 
suggesting apoptosis. Vacuoles with different densities and autophagy vesicles with 
double membrane were also present (figure 2d). Sorafenib induced apoptosis with 
shrinkage of the cytoplasm (figure 2e).  
Discussion 
Despite several trials, there are no effective vaccines against Leishmania up to now 
and chemotherapy remains the mainstay for the control of leishmaniasis. The 
currently used drugs are unsafe, expensive, and lead to resistance (40). Moreover, 
treatment of leishmaniasis with protease inhibitors has been tried before in several 
research studies. Accordingly, in this study, we evaluated the effect of three different, 
commercially available, enzyme inhibitors against L. infantum spp. We compared the 
mono and combination therapy of auranofin, lopinavir / ritonavir (aluvia) and 
sorafenib. The drugs were chosen for their well-known history of safe clinical profile 
and for their inhibition of essential enzymes (41). 
The current results showed that auranofin had the most effective anti-leishmanial 
activity among the tested drugs. It is the only drug that when used individually led to 
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a significant inhibition in the parasite count compared to AmB. At 10 µM auranofin 
also significantly reduced the parasite count more than sorafenib but the results were 
insignificant compared to that of aluvia. Furthermore, auranofin gave the lowest 
growth percentage of the parasite and had the lowest LC50 in comparison to aluvia, 
sorafenib and AmB. The effect of auranofin against L. infantum is due to inhibition of 
trypothione reductase enzyme; one of the top targets in drug discovery for 
leishmaniasis as it protects the parasite from oxidative damage and toxic heavy 
metals and allows the delivery of the reducing equivalents for DNA synthesis (14,42). 
Aluvia was found to be higher in efficacy than of AmB. The proteolytic activity of the 
HIV PIs had been demonstrated by other studies of different Leishmania species 
(21,24,25,43). Another mode of action was explained by Alves et al (44), through 
modulation of innate defense mechanisms via different cellular pathways. They also 
showed that although HIV protease inhibitors are highly efficient to control HIV, these 
drugs might also influence the course of leishmaniasis in HIV-Leishmania-co-
infected individuals. 
In the present study, sorafenib showed the least leishmanicidal activity among the 
studied drugs. It didn’t significantly reduce the promastigotes than AmB and had a 
higher LC50. The drug is a multi-kinase inhibitor and was found to be active against 
L. donovani in culture identifying cycline dependent kinase and mitogen activated 
kinase as targets for anti-leishmanial treatment (26,27). Recently, it was found that 
sorafenib utilizes a non-apoptotic form of cell death (ferroptosis) to perform its effect 
on tumor cells. Ferroptosis is a regulated form of cell death results from iron-
dependent lipid peroxide accumulation as shown by Yu et al (45). 
Combination therapy between commercially available drugs aims at reducing cost, 
toxicity and duration of treatment and represents a promising alternative rational 
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(46). Therefore, we tried the combination of these drugs in a two-way and in a three-
way combinations. The results showed that the interactions between the drugs in the 
two-way combination were found to be additive. More importantly, the combination of 
the three drugs showed synergetic effect. Although the present results showed that 
neither aluvia nor sorafenib gave significant inhibition in the parasite when used 
individually, significant reduction was achieved by the combination of both drugs 
(combination B). Butcher attributed this unexpected result to the combination 
between two drugs with two different defined biomolecular targets (47). Furthermore, 
the combination between auranofin and aluvia (combination A) led to significant 
reduction in the parasite count than AmB and this could be due to the strong anti-
leishmanial effect of auranofin added to that, the different mechanism of action of 
aluvia in modulating the immune system. Lewis et al supports our findings in animal 
model where a combination of auranofin and antiretroviral drug was able to 
significantly reduce the post-therapy viremia (48). 
The use of drugs with synergistic or additive activity in combination therapy delays or 
prevents the development of resistance and may shorten the treatment regimen 
which in turn decreases the undesirable effects made by each drug (49,50). 
Moreover, this alternative strategy leads to reduction of cost and time (41). The 
search for synergism by combination of approved drugs can rapidly move the results 
into preclinical and clinical phases (51). 
In an attempt to explore the effect of each drug on the promastigotes, ultrastructural 
studies of treated parasites were done. SEM of the promastigotes treated by 
auranofin, aluvia and sorafenib for 48 hours showed sever distortion in the shape, 
loss of flagella with irregularities on the cell surface. Some promastigotes treated 
with auranofin exhibited a rounded appearance. Sharlow et al found the same 
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morphology of the promastigotes of L. amazonensis treated by auranofin (52). 
Rigobello et al (13) and Ilari et al (14) attributed this rounded swelling to the inhibition 
of trypanothione reductase and to the membrane permeability transition. This 
morphological distortion had not been observed with any known leishmanicidal drugs 
(52). 
In the current work, the TEM showed evidences suggested that auranofin, aluvia and 
sorafenib exerted their anti-leishmanial effect on L. infantum promastigotes by 
inducing apoptosis. There were some changes in the essential organelles including 
the nucleus, the mitochondria and the cell membrane in addition to changes in the 
cytoplasmic contents. There were also irregularities of the cell membrane. The most 
striking ultrastructure change was the presence of large number of acidocalcisomes 
in the cytoplasm which is an important evidence of apoptosis (53). Only the 
promastigotes that were treated with aluvia showed autophagy in addition to 
apoptosis. The increased number of the vesicles with different densities in the 
cytoplasm, rupture of the nuclear envelope and the presence of dense chromatic 
granules represent signs of autophagy (24,54). The two major forms of programmed 
cell death, the apoptosis and autophagy were also verified in the ultrastructure study 
of L. amazonensis treated by HIV PIs (24). 
Therefore, it can be concluded that administration of the combination of drugs is 
more effective and superior than individual drugs. The combined administration of 
the drugs in two way combinations led to additive interactions. Furthermore, the 
combination of the three drugs had shown synergistic action. The synergism shown 
with the combined drugs brings us to the concept of structure-function approach in 
fighting leishmaniasis. The electron microscopic study revealed that the three drugs 
exerted their anti-leishmanial action by inducing apoptosis, in addition to autophagy 
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in case of aluvia. It is possible that the effectivity of this drug combination is 
attributed to their similar mechanisms of action. However, further experimental 
design to establish the curative combination ratio and toxicity parameters of these 
compounds is needed. Also, further studies to test drug effectivity on amastigotes 
are to be done in the future. 
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Table 1. Effect of different drugs on in vitro proliferation of L. infantum promastigotes 
Drug Growth percentage 
Auranofin (Ridaura 3mg) 4.27% 
Lopinavir/ Ritonavir (Aluvia 200mg) 6.8% 
Sorafenib (Nexavar 200mg) 9.84% 
Amphotericin B 11% 
Auranofin+ lopinavir/ ritonavir (Combination A) 3.75% 
Lopinavir/ ritonavir+ sorafenib(Combination B) 5.1% 
Auranofin+ sorafenib (Combination C) 8.25% 
Auranofin+ sorafenib+ lopinavir/ ritonavir (Combination D) 4.75% 
Leishmanicidal effect of the drugs is tested after 48h of incubation with the parasite 
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Table 2. EC50 of different drugs (EC50) 
Drug EC50 (μM) 
Auranofin (Ridaura 3mg)  1.5 µM 
Lopinavir/ Ritonavir (Aluvia 200mg) 1.7 µM 
 Sorafenib (Nexavar 200mg) 2.5 µM 
Amphotericin B 2 µM 
EC50 values are means of triplicate assays 
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Table 3. EC25 of different drugs in every combination 
Drug Lopinavir/Ritonavir Auranofin Sorafenib 
Auranofin+ Lopinavir/ Ritonavir 
(combination A) 
0.77 µM 2.3 µM  
Lopinavir/ Ritonavir+ sorafenib(combination 
B) 
1 µM  2 µM 
Auranofin+ sorafenib(combination C)  1.8 µM 1.2 µM 
Auranofin+ sorafenib+Lopinavir/ 
Ritonavir(combination D) 
0.3 µM 0.3 µM 0.3 µM 
EC25 values are means of triplicate assays 
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Table 4. In vitro activity of different drugs and combinations against promastigotes 
Abnormally distributed data was expressed using Median (Min. – Max.) and was compared using 
Kruskal Wallis test, Sig. bet. grps was done using Mann Whitney test 
*: Statistically significant at p ≤ 0.05  
Different superscripts are statically significant 
  
Parasite count in culture media treated with different drugs Median (Min. – Max.) 
Auranofin (Ridaura 300 mg) 38 (27 – 77.5)b 
Lopinavir/ Ritonavir (Aluvia 200mg) 70 (18 – 100)ab 
Sorafenib (Nexavar 200mg) 101 (40 – 150)a 
Amphotericin B 107.5 (88 – 137)a 
Auranofin+ Lopinavir/ Ritonavir (combination A) 37.5 (15 – 60)b 
Lopinavir/ Ritonavir+ sorafenib(combination B) 51 (20 – 82)b 
Auranofin+ sorafenib (combination C) 82.5 (45 – 120)ab 
Auranofin+ sorafenib+Lopinavir/ Ritonavir (combination D) 40 (20 – 90)b 
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Figure 1. Ultrastructural changes observed in promastigotes from different studied 
media. a and b: Normal shape of the parasite from 48 hours’ culture that were 
inoculated in fresh media in absence of any drug. c: Parasite after being treated with 
auranofin showed shape distortion, loss of flagella and some of them showing a 
round form (arrow). d: Severe distortion in the shape and loss of flagella with 
detached membrane in aluvia treated promastigote. e: Promastigote treated with 
sorafenib showed a large dimple (arrow) on body surface in addition to loss of 
flagella. 
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Figure 2. Ultrastructural changes in promastigotes from different media. a and b: 
normal parasite from 48 hours culture that were inoculated in fresh media in absence 
of any drug. c: Auranofin treated promastigotes showed well evident acidocalcinosis 
(arrows). d: Aluvia treated promastigotes showed well evident acidocalcinosis (thick 
arrow) and degenerated nuclear membrane (thin arrow) with condensed chromatin 
granules close to the nuclear membrane suggesting apoptosis. Vacuoles with 
different densities and autophagy vesicles with double membrane were also present. 
e: Sorafenib treated promastigotes showed acidocalcinosis and shrinkage of the 
cytoplasm (arrow). 
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